Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

55.56USD
17 Jan 2017
Change (% chg)

$-0.66 (-1.17%)
Prev Close
$56.22
Open
$55.89
Day's High
$55.89
Day's Low
$55.21
Volume
1,476,027
Avg. Vol
11,350,288
52-wk High
$77.12
52-wk Low
$49.03

BMY

Chart for BMY

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $93,956.55
Shares Outstanding(Mil.): 1,671.23
Dividend: 0.39
Yield (%): 2.77

Financials

  BMY Industry Sector
P/E (TTM): 28.00 29.84 30.76
EPS (TTM): 2.01 -- --
ROI: 13.97 15.39 14.82
ROE: 21.93 16.58 16.24

BRIEF-Bristol-Myers sees operating expenses flat through 2020

* Bristol-Myers Squibb CEO says expects oncology portfolio to be impacted by competition in 2017, particularly in lung cancer

Jan 10 2017

BRIEF-Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb

* Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb

Jan 09 2017

BRIEF-Bristol-Myers Squibb and genecentric diagnostics announces exploratory biomarker research collaboration

* Bristol-Myers Squibb and genecentric diagnostics announce exploratory biomarker research collaboration

Jan 06 2017

Deutsche Bank to pay $95 million to end U.S. tax fraud case

NEW YORK Deutsche Bank AG agreed to pay $95 million to resolve a U.S. government lawsuit accusing the German bank of tax fraud for using "insolvent" shell companies to hide significant tax liabilities from the Internal Revenue Service in 2000.

Jan 05 2017

Ono warns on profit after government halves price of cancer drug Opdivo

TOKYO Ono Pharmaceutical Co cut its annual profit outlook by a quarter on Wednesday, hit by the Japanese government's decision to halve the price of cancer drug Opdivo that it co-developed with Bristol Myers Squibb Co.

Dec 21 2016

Bristol-Myers Squibb to pay $19.5 million to settle off-label promotion case

WASHINGTON Drugmaker Bristol-Myers Squibb Co will pay $19.5 million to resolve multi-state allegations that it improperly promoted a schizophrenia treatment for uses not approved by the U.S. government, New York Attorney General Eric Schneiderman said on Thursday.

Dec 08 2016

EU clears Bristol-Myers immunotherapy drug for blood cancer

LONDON Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.

Dec 06 2016

BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin

Nov 22 2016

BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe

* Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe Source text for Eikon: Further company coverage:

Nov 22 2016

UPDATE 1-Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug

* Japan set cut due to high price of drug, Ono confirms (Adds Japan price details)

Nov 16 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $114.29 -0.31
Pfizer Inc. (PFE.N) $31.92 -0.60
Merck & Co., Inc. (MRK.N) $61.37 -0.97
Sanofi SA (SASY.PA) €75.89 -0.92
AstraZeneca plc (AZN.L) 4,535.50p -40.00
GlaxoSmithKline plc (GSK.L) 1,554.25p -26.50
Eli Lilly and Co (LLY.N) $76.16 -1.24
Roche Holding Ltd. (ROG.S) CHF234.70 -0.90
Roche Holding Ltd. (RO.S) CHF239.10 -1.20

Earnings vs. Estimates